CDT Equity Inc.

Healthcare · Biotechnology · United States

Last price 0.077 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 86.59K

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also ...